United States

Exact Sciences Corp (EXAS.OQ)

EXAS.OQ on NASDAQ Stock Exchange Capital Market

4:00pm EDT
Change (% chg)

$-0.13 (-0.43%)
Prev Close
Day's High
Day's Low
Avg. Vol
52-wk High
52-wk Low


Chart for EXAS.OQ


Exact Sciences Corporation is a molecular diagnostics company. The Company focuses on the early detection and prevention of some forms of cancer. It offers a non-invasive screening test called Cologuard for the early detection of colorectal cancer and pre-cancer. Its Cologuard test is a stool-based deoxyribonucleic acid (sDNA)... (more)


Beta: 0.83
Market Cap(Mil.): $3,333.60
Shares Outstanding(Mil.): 110.60
Dividend: --
Yield (%): --


  EXAS.OQ Industry Sector
P/E (TTM): -- 58.07 30.12
EPS (TTM): -1.47 -- --
ROI: -49.94 0.23 13.28
ROE: -51.75 6.18 14.44

BRIEF-Exact Sciences posts Q1 loss per share $0.32

* Exact Sciences Corp - company anticipates revenue of $195 million-$205 million and completed Cologuard test volume of at least 470,000 tests during 2017 Source text for Eikon: Further company coverage:

Apr 27 2017

BRIEF-Mdxhealth and Exact Sciences sign collaboration agreement

* Mdxhealth and Exact Sciences sign collaboration agreement for collaboration in the growing field of epigenetics and molecular diagnostics

Apr 27 2017

BRIEF-Exact sciences Q4 loss per share $0.34

* Q4 earnings per share view $-0.39 -- Thomson Reuters I/B/E/S

Feb 21 2017

BRIEF-Exact Sciences appoints Jeff Elliott as CFO

* Exact Sciences appoints Jeff Elliott chief financial officer Source text for Eikon: Further company coverage:

Nov 08 2016

More From Around the Web


  Price Chg
Quest Diagnostics Inc (DGX.N) $105.51 -0.30
Epigenomics AG (ECXn.F) €7.20 +0.11
GeneNews Ltd (GEN.TO) $0.30 -0.01

Earnings vs. Estimates